See more : Genovate Biotechnology Co., Ltd. (4130.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Rallybio Corporation (RLYB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rallybio Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Shoei Yakuhin Co.,Ltd. (3537.T) Income Statement Analysis – Financial Results
- NewMarket Corporation (NEU) Income Statement Analysis – Financial Results
- Taoka Chemical Company, Limited (4113.T) Income Statement Analysis – Financial Results
- Viad Corp (VVI) Income Statement Analysis – Financial Results
- Gohigh Networks Co., Ltd. (000851.SZ) Income Statement Analysis – Financial Results
Rallybio Corporation (RLYB)
About Rallybio Corporation
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 150.00K | 167.00K | 109.00K | 62.03K | 26.34K |
| Gross Profit | -150.00K | -167.00K | -109.00K | -62.03K | -26.34K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 53.54M | 40.69M | 26.91M | 17.63M | 11.37M |
| General & Administrative | 25.39M | 27.20M | 18.74M | 7.67M | 6.28M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.39M | 27.20M | 18.74M | 7.67M | 6.28M |
| Other Expenses | 0.00 | 342.00K | 96.00K | 241.00K | 24.00K |
| Operating Expenses | 78.93M | 67.88M | 45.65M | 25.30M | 17.64M |
| Cost & Expenses | 78.93M | 67.88M | 45.65M | 25.30M | 17.64M |
| Interest Income | 6.15M | 1.96M | 54.00K | 171.00K | 197.00K |
| Interest Expense | 0.00 | 0.00 | 10.00K | 49.00K | 39.00K |
| Depreciation & Amortization | 150.00K | 167.00K | 109.00K | 62.03K | 26.34K |
| EBITDA | -72.37M | -65.41M | -45.39M | -24.83M | -17.39M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -78.93M | -67.88M | -45.65M | -25.30M | -17.64M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.37M | 2.31M | 140.00K | 363.00K | 182.00K |
| Income Before Tax | -74.56M | -65.58M | -45.51M | -24.94M | -17.46M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.04M | 908.00K | 1.50M | -15.00K | 166.00K |
| Net Income | -74.56M | -66.49M | -47.01M | -24.93M | -17.63M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.84 | -2.09 | -1.46 | -0.78 | -0.55 |
| EPS Diluted | -1.84 | -2.09 | -1.46 | -0.78 | -0.55 |
| Weighted Avg Shares Out | 40.45M | 31.82M | 32.13M | 32.13M | 32.13M |
| Weighted Avg Shares Out (Dil) | 40.45M | 31.82M | 32.13M | 32.13M | 32.13M |
Rallybio Corporation Reports Second Quarter 2021 Financial Results and Recent Business Highlights
Andreas Halvorsen Gets a Healthy Dose of Rallybio
Rallybio Corporation Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Rallybio Corporation Announces Pricing of Initial Public Offering
Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020
Source: https://incomestatements.info
Category: Stock Reports